Compare Google Inc (GOOG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs IDEXX Laboratories, Inc. — how do they compare? Google Inc trades at $347.86 (market cap $4.24T), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Google Inc is far larger — about 104.9× IDEXX Laboratories, Inc.'s market cap, and Google Inc pays a 0.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GOOG | IDXX | |
|---|---|---|
Market Cap | $4.24T | $40.43B |
Volume | 13,937,902 | 692,164 |
Sector | Media | Health |
52-Week High | $399.06 | $766.68 |
52-Week Low | $237.49 | $504.70 |
Typical Hold Time | 137 Days | 46 Days |
Enterprise Value | $4.13T | $41.32B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $347.86, up 0.14% with strong technical momentum above key support levels. The stock shows robust fundamentals with revenue growth accelerating to $402.84B in 2025 and net income margins expanding to 32.8%. Recent earnings beats and a bullish analyst consensus at 87% buy ratings support the positive outlook, though elevated capital expenditures and regulatory scrutiny present near-term headwinds.
Alphabet's outlook remains favorable with AI-driven cloud growth and consistent earnings outperformance. The stock trades at a reasonable 17.3 P/E with 34% upside to the $435.24 consensus target. Key risks include massive AI infrastructure spending impacting cash flow and ongoing regulatory litigation. The technical setup suggests continued momentum toward resistance at $352-$354.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
